Why the study?
Device-related thrombus after LAAC is associated with adverse outcomes, but data on predictors of stroke or systemic embolism in the context of DRT are limited.
What are the predisposing factors and temporal characteristics of stroke or systemic embolism in patients with device-related thrombus after left atrial appendage closure?
What are the predisposing factors and temporal characteristics of stroke or systemic embolism in patients with device-related thrombus after left atrial appendage closure?
Answers are grounded in this paper and cite their sources.
In patients with device-related thrombus after LAAC, stroke or systemic embolism occurs in 14.2% of cases and is associated with lower LVEF, highlighting a substantial ischemic risk.
BACKGROUND: Device-related thrombus (DRT) after left atrial appendage closure (LAAC) is associated with adverse outcomes, i.e. ischemic stroke or systemic embolism (SE). Data on predictors of stroke/SE in the context of DRT are limited. AIMS: This study aimed to identify predisposing factors for stroke/SE in DRT patients. In addition, the temporal connection of stroke/SE to DRT diagnosis was analyzed. METHODS: The EUROC-DRT registry included 176 patients, in whom DRT after LAAC were diagnosed. Patients with symptomatic DRT, defined as stroke/SE in the context of DRT diagnosis, were compared against patients with non-symptomatic DRT. Baseline characteristics, anti-thrombotic regimens, device position, and timing of stroke/SE were compared. RESULTS: Stroke/SE occurred in 25/176 (14.2%) patients diagnosed with DRT (symptomatic DRT). Stroke/SE occurred after a median of 198 days (IQR 37-558) after LAAC. In 45.8% stroke/SE occurred within one month before/after DRT diagnosis (DRT-related stroke). Patients with symptomatic DRT had lower left ventricular ejection fractions (50.0 ± 9.1% vs. 54.2 ± 11.0%, p = 0.03) and higher rates of non-paroxysmal atrial fibrillation (84.0% vs. 64.9%, p = 0.06). Other baseline parameters and device positions were not different. Most ischemic events occurred among patients with single antiplatelet therapy (50%), however, stroke/SE was also observed under dual antiplatelet therapy (25%) or oral anticoagulation (20%). CONCLUSION: Stroke/SE are documented in 14.2% and occur both in close temporal relation to the DRT finding and chronologically independently therefrom. Identification of risk factors remains cumbersome, putting all DRT patients at substantial risk for stroke/SE. Further studies are necessary to minimize the risk of DRT and ischemic events.
No takes yet. Share an insight, caveat, or question.
Vij et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: